IBC Meeting Minutes Cleveland Clinic Florida Research and Innovation Center

Date:		Location:					
September 18 th , 2025		Zoom					
IBC Member Attendance:							
☐ McDonald, Christine (IBC Chair)	⊠ Li,	Kun	⊠ Such, Kimberly				
☐ Champer, Dylan (BSO/Acting Chair)	⊠ Ha	jjar, Adeline	☑ Judd, Leslie				
⊠ Tavakoli, Sara	⊠ O'	Connor, Christine	☑ Doud, Melissa				
Guests: Amanda Dragan*, Anthony Santilli*, Nikki Meyer* *Cleveland Clinic Main Campus							
Call To Order:		Adjourn:					
2:33 pm		3:12 pm					

I. Review of August 21st, 2025 Meeting Minutes

Committee Comments: None			
Motion:	For:	Against:	Abstain:
Approval	9	0	0

II. Non-Clinical Research:

a. Renewals:

Basic Research	Protocol ID:	PI:	Biosafety Level:	NIH Cat.:					
Renewal # 1	FLIBC015	Thomas BSL-2, BSL-2+ II		III-D-1-a					
Project Titles:									
Sample preparation, cell sorting and flow-cytometric analysis of unfixed samples requiring BSL-2/BSL-2+ containment									
Associated Grant N	Associated Grant Numbers:								
Non-NIH Funding									

Protocol Summary:								
Sample prepa	ration,	cell sorti	ng and fl	ow c	ytometric	analysis of	fixed and u	ınfixed
samples conta	_		-	_	_			•
for each investigator, before use on Core equipment; Human derived materials.								
Function/Nature of Recombinant Genes to be Expressed:								
⊠ N/A □ Oncogene □ Tumor Suppressor Gene □ Structural □ Signaling □ Antimicrobial								
☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☒ Other								
Species of Recombin	ant Gei	nes to he	Evnresse	-d·				
\boxtimes N/A \square Human \square			_		□ Viral	□ Other		
	⊐ IVIUIII	ic 🗀 Kai	_ Dack	Cilai	□ viiai			
Risk Assessment Dis	cussio	n:			Facilitie	s, Procedu	res, and Sa	ıfety
⊠ Yes □ No						s Reviewed		v
					⊠ Yes	□ No		
Discussion/Required	l Modi	fications	:					
 Administrativ 	e edits							
PI/Supervisor Training (Y/N): Handler Training (Y/N):								
Yes □ No	mg (1/	11).					1/11).	
Motion:								
Approved with		Fo	r:	A	gainst:	Abstain:	Recuse:	Not
Administrative Revis	ions	8			0 1		0	Present:
								0
Basic Research	Droto	col ID:	PI:		Piosof	oty I ovol:	NI	U Cot :
Renewal # 2		BC014	Cao		Biosafety Level: BSL-3		NIH Cat.: III-D-1-a, III-D-4-b	
Project Titles:	1 1/11	JC014	Cao	,	<u>D</u>	<u>5L-3</u>	III-D-1-	-a, III-D- 1 -0
Live-cell imaging of	sample	s reauirir	ng BSL-3	3 con	tainment i	n order to i	nterrogate 1	the complex
biological pathways i	-	-	_					r
Associated Grant N								
Non-NIH Funding								
Protocol Summary:								
 Imaging of live 			-		_		_	`
viruses, cells,					-			each
investigator, b	before t	ise on Co	re equip	ment	; Human d	ierived mat	eriais.	
Function/Nature of R	ecomb	inant Ger	nes to he	Evn	·essed·			
N/A □ Oncogene						☐ Signali	no □ ∆nti	microbial
☐ Immunomodulatory						_	-	microolar
	□ 10A	ш ЦАП	HOIOHC IX		ince 🗀 ixe	porters 🗆 (Juici	
Species of Recombin	ant Gei	nes to be	Expresse	ed:				
\boxtimes N/A \square Human \square Murine \square Rat \square Bacterial \square Viral \square Other								

Risk Assessment Discussion: ⊠ Yes □ No				Facilities, Procedures, and Safety Practices Reviewed (Y/N):					
Z ICS L NO		Yes □ No							
Discussion/Required	ve edits ty inforr	nation in		d SO	P				
PI/Supervisor Train		Handle	r Training (Y/N):					
⊠ Yes □ No	⊠ Yes	□ No	T	T					
Motion: Approved with Administrative Revis			A	gainst:	Abstain:	Recuse:	Not Present:		
				•					
Basic Research Renewal # 3		col ID: BC016	PI: Li			fety Level: 2, BSL-2+	NIH Cat.: III-D-1-a, III-D-2-a, III-D-3-a III-D-4-b, III-E		
Project Titles: Using pseudoviruses			ntry and	inhil	oitors				
Associated Grant N Non-NIH Funding	umbers								
• Acquisition a recombinant MERS-CoV 1 administration	nd prop Vesicula pseudov	ir Stomat irus parti	titis Viru icles in c	ıs (VS cultur	SV), gener e; infection	ration of SA on of cell lin	RS-CoV-2 les, in vivo		
Function/Nature of R □ N/A □ Oncogene □ Immunomodulatory	☐ Tum	or Suppre	essor Gen	ne 🗵	Structura	_	-	microbial	
Species of Recombin □ N/A ⊠ Human			_		□ Viral	⊠ Other			
Risk Assessment Discussion: Facilities, Procedures, and Safety □ Yes □ No Practices Reviewed (Y/N): □ No						afety			
Discussion/Required	d Modif	fications	:						
Biosafety lev									
• Clarification	on bacte	ria							

Safety practices for handling animalsAdministrative edits									
PI/Supervisor Train ⊠ Yes □ No	ing (Y	'N):			Handler ⊠ Yes	r Training (□ No	Y/N):		
Motion: Approved with Administrative Revis			For: 8		gainst:	Abstain:	Recuse:	Not Present:	
	Prote	ocol ID:	PI:		Riosaf	ety Level·	NI	H Cat.:	
Basic Research Renewal # 4		BC017	Li		Biosafety Level: BSL-3		III-D-1	III-D-1-b, III-D-2- a, III-D-3-a, III-D- 4-b	
Project Titles: Host-pathogen intera	ctions o	luring Co	oronaviru	ıs inf	ection		,		
Associated Grant N Non-NIH Funding	Associated Grant Numbers: Non-NIH Funding								
• Acquisition as Coronavirus (2 (SARSr-Co cells, adminis mice; Transfe	nd prop MERS V2), ge tration	-CoV) a neration of virus	nd Sever of SARS in vivo; A	re acu S-Co' Acqui	ite respirate V2 strains is it ion of a	tory syndron , transduction denovirus a	me-related on of tissue	coronavirus	
Function/Nature of R □ N/A □ Oncogene □ Immunomodulatory	□ Tun	or Suppr	essor Gen	ne 🗵	Structural	_	_	microbial	
Species of Recombin □ N/A ⊠ Human □			_		□ Viral	☑ Other			
Risk Assessment Discussion: □ Yes □ No Facilities, Procedures, and Safety Practices Reviewed (Y/N): □ Yes □ No									
 Discussion/Required Biosafety level Biosafety level Permit inform Safety practice 	el of ce el of vin nation ees for l	Il lines ruses nandling	animals						
 PPE for anim. 	ai oena	viorai tes	SIS						

Administrative edits									
PI/Supervisor Train	ing (Y/	N):		Handler Training (Y/N):					
⊠ Yes □ No	1	 	⊠ Yes	□ No	T .	г			
Motion: Approved with Administrative Revis	ions	Fo 8	-	A :	gainst:	Abstain:	Recuse:	Not Present:	
b. Amendment	•								
Basic Research Amendment # 1	Protocol ID: FLIBC001		PI: Gacl		BSL-	fety Level: 1, BSL-2, +, ABSL-2	III-F-1, F-3, III 1-a, III D-3-a,	NIH Cat.: III-F-1, III-F-2, III- F-3, III-F-8, III-D- 1-a, III-D-2-a, III- D-3-a, III-D-4-b, III-D-7, III-E	
Project Titles: Regulation of Host A			mmunity	r					
Associated Grant No NIH (2023): 5DP1AI 14, 1 R21 AI174534-	[169444	1-03, 5R0			04, 5R01	AI165502-0)3, 5 R37 A	.I087846-	
Propagation of recom administration of viru recombinant and wild	Summary of Approved Items: Propagation of recombinant and non-recombinant viruses, transduction of tissue culture cells, administration of viruses and viral transduced cells <i>in vivo</i> ; Generation and propagation of recombinant and wild type SARS-CoV-2 virus, infection of cell lines and experimental analyses, administration of recombinant and wild type SARS-CoV-2 virus <i>in vivo</i> ; Humanderived materials.								
Requested Additions	s/Chan	ges:							
• None									
Function/Nature of R □ N/A □ Oncogene □ Immunomodulatory Species of Recombin □ N/A □ Human □	☐ Tun Toxi ant Ger	nor Supp n □ An	ressor Ge tibiotic R Expresse	ene esista	□ Structu	eporters \Box (-	ntimicrobial	
Risk Assessment Dis ⊠ Yes □ No	cussion	n:				es, Procedures Reviewed		nfety	
Discussion/Required	1 Modi	 fications	:						

None					
PI/Supervisor Training (Y/ ⊠ Yes □ No	/N):	Handler × Yes	r Training (□ No	(Y/N):	
Motion: Approval	For:	Against:	Abstain:	Recuse:	Not Present:

III. Updated SOPs:

SOP a: Biomedical Waste Operating Plan	Comments: Administrative edits				
Motion:	For:	Against:	Abstain:	Recuse:	
Approved with Administrative Revisions	9	0	0	0	

SOP b: Validation Procedures for 4% paraformaldehyde Fixation of Coronaviridae Infected Cells	Comments	s: Administr	ative edits	
Motion:	For:	Against:	Abstain:	Recuse:
Approved with Administrative Revisions	8	0	1	0